Literature DB >> 19420076

Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice.

Diana M Brainard1, Edward Seung, Nicole Frahm, Annaiah Cariappa, Charles C Bailey, William K Hart, Hae-Sook Shin, Sarah F Brooks, Heather L Knight, Quentin Eichbaum, Yong-Guang Yang, Megan Sykes, Bruce D Walker, Gordon J Freeman, Shiv Pillai, Susan V Westmoreland, Christian Brander, Andrew D Luster, Andrew M Tager.   

Abstract

The generation of humanized BLT mice by the cotransplantation of human fetal thymus and liver tissues and CD34(+) fetal liver cells into nonobese diabetic/severe combined immunodeficiency mice allows for the long-term reconstitution of a functional human immune system, with human T cells, B cells, dendritic cells, and monocytes/macrophages repopulating mouse tissues. Here, we show that humanized BLT mice sustained high-level disseminated human immunodeficiency virus (HIV) infection, resulting in CD4(+) T-cell depletion and generalized immune activation. Following infection, HIV-specific humoral responses were present in all mice by 3 months, and HIV-specific CD4(+) and CD8(+) T-cell responses were detected in the majority of mice tested after 9 weeks of infection. Despite robust HIV-specific responses, however, viral loads remained elevated in infected BLT mice, raising the possibility that these responses are dysfunctional. The increased T-cell expression of the negative costimulator PD-1 recently has been postulated to contribute to T-cell dysfunction in chronic HIV infection. As seen in human infection, both CD4(+) and CD8(+) T cells demonstrated increased PD-1 expression in HIV-infected BLT mice, and PD-1 levels in these cells correlated positively with viral load and inversely with CD4(+) cell levels. The ability of humanized BLT mice to generate both cellular and humoral immune responses to HIV will allow the further investigation of human HIV-specific immune responses in vivo and suggests that these mice are able to provide a platform to assess candidate HIV vaccines and other immunotherapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420076      PMCID: PMC2704767          DOI: 10.1128/JVI.02207-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Multiparameter flow cytometric analysis of human fetal bone marrow B cells.

Authors:  T W LeBien; B Wörmann; J G Villablanca; C L Law; L M Steinberg; V O Shah; M R Loken
Journal:  Leukemia       Date:  1990-05       Impact factor: 11.528

2.  Distinctive development of IgG4 subclass antibodies in the primary and secondary responses to keyhole limpet haemocyanin in man.

Authors:  P Bird; J E Calvert; P L Amlot
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

Review 3.  Emerging concepts in the immunopathogenesis of AIDS.

Authors:  Daniel C Douek; Mario Roederer; Richard A Koup
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

4.  Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection.

Authors:  P Lorès; V Boucher; C Mackay; M Pla; H Von Boehmer; J Jami; F Barré-Sinoussi; J C Weill
Journal:  AIDS Res Hum Retroviruses       Date:  1992-12       Impact factor: 2.205

5.  Infection of the SCID-hu mouse by HIV-1.

Authors:  R Namikawa; H Kaneshima; M Lieberman; I L Weissman; J M McCune
Journal:  Science       Date:  1988-12-23       Impact factor: 47.728

6.  Transfer of a functional human immune system to mice with severe combined immunodeficiency.

Authors:  D E Mosier; R J Gulizia; S M Baird; D B Wilson
Journal:  Nature       Date:  1988-09-15       Impact factor: 49.962

7.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.

Authors:  J M McCune; R Namikawa; H Kaneshima; L D Shultz; M Lieberman; I L Weissman
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

8.  Human immunodeficiency virus infection of human-PBL-SCID mice.

Authors:  D E Mosier; R J Gulizia; S M Baird; D B Wilson; D H Spector; S A Spector
Journal:  Science       Date:  1991-02-15       Impact factor: 47.728

9.  B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase.

Authors:  Annaiah Cariappa; Hiromu Takematsu; Haoyuan Liu; Sandra Diaz; Khaleda Haider; Cristian Boboila; Geetika Kalloo; Michelle Connole; Hai Ning Shi; Nissi Varki; Ajit Varki; Shiv Pillai
Journal:  J Exp Med       Date:  2008-12-22       Impact factor: 14.307

10.  Enhancing SIV-specific immunity in vivo by PD-1 blockade.

Authors:  Vijayakumar Velu; Kehmia Titanji; Baogong Zhu; Sajid Husain; Annette Pladevega; Lilin Lai; Thomas H Vanderford; Lakshmi Chennareddi; Guido Silvestri; Gordon J Freeman; Rafi Ahmed; Rama Rao Amara
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

View more
  160 in total

Review 1.  Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice.

Authors:  Paul W Denton; J Victor Garcia
Journal:  Trends Microbiol       Date:  2012-04-12       Impact factor: 17.079

Review 2.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

Review 3.  Human lymphohematopoietic reconstitution and immune function in immunodeficient mice receiving cotransplantation of human thymic tissue and CD34(+) cells.

Authors:  Zheng Hu; Yong-Guang Yang
Journal:  Cell Mol Immunol       Date:  2012-02-06       Impact factor: 11.530

4.  BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection.

Authors:  Kerry J Lavender; Wendy W Pang; Ronald J Messer; Amanda K Duley; Brent Race; Katie Phillips; Dana Scott; Karin E Peterson; Charles K Chan; Ulf Dittmer; Timothy Dudek; Todd M Allen; Irving L Weissman; Kim J Hasenkrug
Journal:  Blood       Date:  2013-09-10       Impact factor: 22.113

5.  Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3.

Authors:  Jeremy A Goettel; Subhabrata Biswas; Willem S Lexmond; Ada Yeste; Laura Passerini; Bonny Patel; Siyoung Yang; Jiusong Sun; Jodie Ouahed; Dror S Shouval; Katelyn J McCann; Bruce H Horwitz; Diane Mathis; Edgar L Milford; Luigi D Notarangelo; Maria-Grazia Roncarolo; Edda Fiebiger; Wayne A Marasco; Rosa Bacchetta; Francisco J Quintana; Sung-Yun Pai; Christoph Klein; Aleixo M Muise; Scott B Snapper
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 6.  Immune activation and the role of TLRs and TLR agonists in the pathogenesis of HIV-1 infection in the humanized mouse model.

Authors:  J Judy Chang; Marcus Altfeld
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

Review 7.  Humoral immunity in humanized mice: a work in progress.

Authors:  Edward Seung; Andrew M Tager
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

8.  A mouse model for HIV-1 entry.

Authors:  John Pietzsch; Henning Gruell; Stylianos Bournazos; Bridget M Donovan; Florian Klein; Ron Diskin; Michael S Seaman; Pamela J Bjorkman; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

9.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

10.  Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.

Authors:  Anjie Zhen; Valerie Rezek; Cindy Youn; Brianna Lam; Nelson Chang; Jonathan Rick; Mayra Carrillo; Heather Martin; Saro Kasparian; Philip Syed; Nicholas Rice; David G Brooks; Scott G Kitchen
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.